Developer docs
API playgroundTry for free, no card

Search company profiles

DiaMonTech AG

Full company profile

uuid0000vii

Namestring
DiaMonTech AG
Legal namestring
DiaMonTech AG
Websiteurl
diamontech.de
Company typeenum
Private
Founded yearint
2015
Descriptiontext

DiaMonTech AG is a Berlin-based medical device company founded in 2015 that is developing non-invasive blood glucose monitoring technology based on mid-infrared quantum cascade laser (QCL) spectroscopy combined with its patented Infrared Evaluated Photothermal Detection (IRE-PTD) method. The technology scans interstitial fluid in the skin, where glucose levels run at 85–90% of blood glucose and follow changes within approximately five minutes, and detects temperature changes of less than 1/1000 of a degree Celsius to deliver a reading in 10–15 seconds without needles, test strips, or consumables. Clinical studies have reported MARD values of 11.1–20.7% and 99.1% accuracy per Consensus Error Grid Analysis across 100+ participants, comparable to early FDA-approved continuous glucose monitors.

The product portfolio consists of the CE-certified DMT Base for professional diabetes center environments, the D-Pocket handheld consumer device (smartphone-sized, targeted for 2026 launch), the D-Sensor miniaturized wearable being co-developed with Samsung for smartwatch integration, and the Diamoki companion app for longitudinal tracking of glucose, blood pressure, diet, activity, BMI, and medication. The company holds ISO 13485:2016 and ISO 27001 certifications, has filed an FDA pre-submission for the D-Base, and protects its technology with more than 100 patents globally.

DiaMonTech's business model centers on hardware sales (B2B to diabetes centers and B2C to patients and health-conscious consumers), with a strategic push toward reimbursement-driven revenue through health insurance partnerships (notably HanseMerkur) and future recurring software/data value via the Diamoki app. Total funding raised exceeds €32 million across rounds spanning 2018–2025, anchored by Samsung Ventures/Samsung Next, Bioventure, IBB Ventures, Unorthodox Ventures, Moll Family GmbH, and Companisto. The company remains pre-commercial with flagship consumer launch planned for 2026.

Short descriptiontext

DiaMonTech AG is a Berlin-based medtech company developing non-invasive blood glucose monitoring devices using proprietary mid-infrared laser and photothermal detection technology, targeting diabetes patients, healthcare providers, and health-conscious consumers across Europe and the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive glucose monitoring, medical device manufacturing, diabetes management solutions, laser spectroscopy sensors, wearable health technology
Industry4 codes
PRIMARYHLAHAHAG
Blood Glucose Monitoring (BGM) Meters & Test Strips
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAHAA
Continuous Glucose Monitoring (CGM) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAOAB
Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Devices / Non-Invasive Blood Glucose Monitoring
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Hardware Sales - D-Pocket
TypeHardware Sales
Description

Sale of portable non-invasive blood glucose monitoring devices (D-Pocket) to consumers and healthcare providers. Device is smartphone-sized and designed for personal use. No consumables required.

diamontech.de
2Hardware Sales - D-Base/DMT Base
TypeHardware Sales
Description

Sale of professional-grade non-invasive glucose monitoring device optimized for use in diabetes centers and clinical settings. CE-certified medical device.

diamontech.de
3D-Sensor Wearable Technology
TypeHardware Sales
Description

Future revenue stream from miniaturized sensor technology for integration into smartwatches and wearables. Currently in development with Samsung.

diamontech.de
4Diamoki App - Companion Software
TypeSubscription Recurring
Description

Diabetes management companion app for tracking blood glucose, blood pressure, diet, activity, weight/BMI and medication. App can import data from health apps and glucose meters. Currently under development.

diamontech.de
5Strategic Healthcare Partnerships
TypeProfessional Services
Description

Strategic cooperation with health insurance companies like HanseMerkur for providing non-invasive blood glucose measurement services to insured individuals. Potential for reimbursement-driven revenue.

diamontech.de
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details2 tiers
1D-Pocket - Consumer Device
ModelOtherBilling cadenceOne time/ perpetual license
Notes

Pricing not publicly disclosed. Company states no waiting list but investors receive priority access to first devices. Product expected to launch 2026.

diamontech.de
2D-Base - Professional Device
ModelOtherBilling cadenceOne time/ perpetual license
Notes

Pricing not publicly disclosed. CE-certified for professional use in diabetes centers.

diamontech.de
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1D-Pocket
Description

Handheld non-invasive blood glucose monitoring device, smartphone-sized, currently in development. Uses mid-infrared laser technology and photothermal detection for pain-free glucose measurement.

diamontech.de
+3 more records
Core offering1 text field

DiaMonTech AG develops and is commercializing medical devices for non-invasive blood glucose measurement using proprietary mid-infrared quantum cascade laser spectroscopy and its patented IRE-PTD photothermal detection method. Its current portfolio includes the CE-certified DMT Base for professional clinical settings, the in-development D-Pocket handheld consumer device, the in-development D-Sensor miniaturized wearable sensor (co-developed with Samsung), and the Diamoki companion health-tracking app.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • MARD (Mean Absolute Relative Difference) values of 20.7% and 19.6% - comparable to early invasive CGM devices approved by FDA and Notified Body in EU
+4 more records
Product overview1 text field

DiaMonTech AG offers a portfolio of non-invasive blood glucose monitoring products built on its proprietary mid-infrared quantum cascade laser (QCL) technology and patented IRE-PTD (Infrared Excited — Photothermal Detection) method. The core product line consists of three distinct devices: the DMT Base, a CE-certified stationary device for professional clinical environments (diabetes centers); the D-Pocket, a handheld consumer device approximately the size of a smartphone — the flagship portable product currently in development; and the D-Sensor, a miniaturized wearable sensor being developed in partnership with Samsung for integration into smartwatches. These devices share a common underlying technology platform — mid-infrared spectroscopy scanning interstitial fluid in the skin to detect glucose molecules via a heat-wave detection process — but serve different form factors and market segments. Complementing the hardware products, the companion mobile app Diamoki enables users to track glucose, blood pressure, diet, activity, weight/BMI, and medication, with automatic import from health apps and glucometers, providing a unified data analytics layer across the product ecosystem. The company also holds ISO 13485:2016 and ISO 27001:2017 certifications, and has filed over 100 patents globally.

Product and service4 records
1DMT Base (D-Base)
CategoryMedical Devices — Professional Clinical Blood Glucose Monitoring
Description

Non-invasive, CE-certified medical device for professional blood glucose monitoring using mid-infrared QCL laser spectroscopy and patented IRE-PTD photothermal detection. Designed for diabetes centers and clinical settings, providing needle-free, consumable-free glucose measurement with 99.1% clinical accuracy.

2D-Pocket
CategoryMedical Devices — Consumer Blood Glucose Monitoring
Description

Handheld, smartphone-sized, non-invasive blood glucose monitor for consumer use. Uses patented mid-infrared QCL + IRE-PTD technology to deliver pain-free glucose readings within 10–15 seconds without test strips or other consumables. Achieves clinical-grade accuracy comparable to early invasive CGM devices (MARD 20.7% and 19.6%).

3D-Sensor
CategoryMedical Devices — Wearable Continuous Glucose Monitoring Sensor
Description

Miniaturized non-invasive glucose sensor under development with Samsung for integration into smartwatches and wearable devices. Extends DiaMonTech's mid-infrared laser and photothermal detection technology into a continuous-monitoring form factor for both diabetes patients and health-conscious users.

4Diamoki
CategorySoftware — Diabetes Management Companion App
Description

Companion mobile app for diabetes management that tracks blood glucose, blood pressure, diet, activity, weight/BMI, and medication, with automatic import from health apps and glucose meters. Provides trend visualization and structured health-data analytics as the software layer across DiaMonTech's device ecosystem.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Market access initiative for life sciences startups to assist in US market navigation, providing expert mentorship and strategic connections. Supports DiaMonTech's international expansion goals.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-29
Description

One of Germany's largest private health insurance companies (€2.3 billion annual revenue) plans strategic cooperation to provide non-invasive blood glucose measurement to insured customers. First pilot projects for insulin-dependent diabetics planned for 2021. HanseMerkur sees potential for early diabetes detection using DiaMonTech technology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Leading CGM manufacturer (G6, G7) with the strongest accuracy credentials (MARD ~8%) and deepest payer/reimbursement relationships. Broad incumbent and the gold-standard comparison point for any non-invasive entrant; could pursue non-invasive R&D leveraging its clinical evidence base.

TypeBroad incumbent
Description

Manufacturer of Accu-Chek blood glucose meters and one of the largest traditional BGM incumbents globally. Broad incumbent in glucose monitoring with established pharmacy distribution; potential competitor if the company pursues non-invasive BGM replacement or partners with non-invasive entrants.

TypeBroad incumbent
Description

Manufacturer of FreeStyle Libre, the dominant CGM with 5M+ global users and established retail/payer distribution. Broad incumbent in glucose monitoring that DiaMonTech positions itself against in accuracy comparisons; any Abbott move into non-invasive would directly threaten DiaMonTech's window.

TypeBroad incumbent
Description

Major medical device incumbent offering Guardian Connect CGM and insulin pumps. Broad incumbent in diabetes care with substantial R&D resources and integrated insulin-delivery ecosystem; any pivot to non-invasive CGM would directly compete with DiaMonTech's professional and consumer offerings.

TypeEmerging player
Description

Welsh startup developing a non-invasive wearable continuous glucose monitor using proprietary electromagnetic sensing. Early-stage peer pursuing similar miniaturized, no-consumable, continuous monitoring vision as DiaMonTech's D-Sensor program, providing comparable technology-risk profile.

TypeDirect peer
Description

US-based company developing non-invasive glucose monitoring using radiofrequency spectroscopy and its Bio-RFID sensor technology. Closest direct peer to DiaMonTech given its focus on truly non-invasive continuous glucose monitoring for consumer use, pursuing similar FDA pathways and consumer launch timeline.

TypeEmerging player
Description

Developer of Eversense, the only implantable long-term CGM (180-day sensor). Emerging player pursuing alternative continuous monitoring approaches with comparable accuracy to traditional CGMs but via invasive subcutaneous implantation — represents adjacent technology risk if DiaMonTech's non-invasive accuracy falls short.

TypeDirect peer
Description

UK-based developer of sugarBEAT, a non-invasive continuous glucose monitor using a disposable skin patch. Direct competitor in the non-invasive glucose monitoring space targeting both consumer wellness and medical-grade applications, providing useful comparability on regulatory timelines and consumer adoption rates.

9Integrity Applications (GlucoTrack)
TypeDirect peer
Description

Israeli company that developed GlucoTrack, a non-invasive glucose monitor combining ultrasonic, electromagnetic, and thermal sensors for ear-clip measurement. Direct peer despite using different sensing modalities — represents the long history of attempted non-invasive glucose commercialization.

TypeEmerging player
Description

Developer of LifeLeaf, a non-invasive continuous glucose monitoring wearable. Emerging player pursuing similar smartwatch/wearable form factor as DiaMonTech's D-Sensor, though at earlier commercialization stage with different underlying technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DiaMonTech AG

Medical Devices / Non-Invasive Blood Glucose Monitoringdiamontech.de

DiaMonTech AG is a Berlin-based medtech company developing non-invasive blood glucose monitoring devices using proprietary mid-infrared laser and photothermal detection technology, targeting diabetes patients, healthcare providers, and health-conscious consumers across Europe and the United States.

What DiaMonTech AG does

DiaMonTech AG is a Berlin-based medical device company founded in 2015 that is developing non-invasive blood glucose monitoring technology based on mid-infrared quantum cascade laser (QCL) spectroscopy combined with its patented Infrared Evaluated Photothermal Detection (IRE-PTD) method. The technology scans interstitial fluid in the skin, where glucose levels run at 85–90% of blood glucose and follow changes within approximately five minutes, and detects temperature changes of less than 1/1000 of a degree Celsius to deliver a reading in 10–15 seconds without needles, test strips, or consumables. Clinical studies have reported MARD values of 11.1–20.7% and 99.1% accuracy per Consensus Error Grid Analysis across 100+ participants, comparable to early FDA-approved continuous glucose monitors.

The product portfolio consists of the CE-certified DMT Base for professional diabetes center environments, the D-Pocket handheld consumer device (smartphone-sized, targeted for 2026 launch), the D-Sensor miniaturized wearable being co-developed with Samsung for smartwatch integration, and the Diamoki companion app for longitudinal tracking of glucose, blood pressure, diet, activity, BMI, and medication. The company holds ISO 13485:2016 and ISO 27001 certifications, has filed an FDA pre-submission for the D-Base, and protects its technology with more than 100 patents globally.

DiaMonTech's business model centers on hardware sales (B2B to diabetes centers and B2C to patients and health-conscious consumers), with a strategic push toward reimbursement-driven revenue through health insurance partnerships (notably HanseMerkur) and future recurring software/data value via the Diamoki app. Total funding raised exceeds €32 million across rounds spanning 2018–2025, anchored by Samsung Ventures/Samsung Next, Bioventure, IBB Ventures, Unorthodox Ventures, Moll Family GmbH, and Companisto. The company remains pre-commercial with flagship consumer launch planned for 2026.

DiaMonTech AG firmographics

Firmographics
Name
DiaMonTech AG
Legal name
DiaMonTech AG
Website
https://diamontech.de
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
DiaMonTech AG is a Berlin-based medtech company developing non-invasive blood glucose monitoring devices using proprietary mid-infrared laser and photothermal detection technology, targeting diabetes patients, healthcare providers, and health-conscious consumers across Europe and the United States.
Ownership category
akta.pro rank

DiaMonTech AG industry classification

Industry
Product category
Medical Devices / Non-Invasive Blood Glucose Monitoring
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAHAG
Blood Glucose Monitoring (BGM) Meters & Test Strips
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAHAA
Continuous Glucose Monitoring (CGM) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAOAB
Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)

Keywords

  • Non-invasive glucose monitoring
  • Medical device manufacturing
  • Diabetes management solutions
  • Laser spectroscopy sensors
  • Wearable health technology

Where DiaMonTech AG is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

DiaMonTech AG business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Hardware Sales - D-Pocket: Sale of portable non-invasive blood glucose monitoring devices (D-Pocket) to consumers and healthcare providers. Device is smartphone-sized and designed for personal use. No consumables required.
  2. Hardware Sales - D-Base/DMT Base: Sale of professional-grade non-invasive glucose monitoring device optimized for use in diabetes centers and clinical settings. CE-certified medical device.
  3. D-Sensor Wearable Technology: Future revenue stream from miniaturized sensor technology for integration into smartwatches and wearables. Currently in development with Samsung.
  4. Diamoki App - Companion Software: Diabetes management companion app for tracking blood glucose, blood pressure, diet, activity, weight/BMI and medication. App can import data from health apps and glucose meters. Currently under development.
  5. Strategic Healthcare Partnerships: Strategic cooperation with health insurance companies like HanseMerkur for providing non-invasive blood glucose measurement services to insured individuals. Potential for reimbursement-driven revenue.

Pricing tiers

ModelBillingPrice
OtherOne time/ perpetual licenseD-Pocket - Consumer Device
OtherOne time/ perpetual licenseD-Base - Professional Device

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

DiaMonTech AG product offering

Product offering

Core offering

DiaMonTech AG develops and is commercializing medical devices for non-invasive blood glucose measurement using proprietary mid-infrared quantum cascade laser spectroscopy and its patented IRE-PTD photothermal detection method. Its current portfolio includes the CE-certified DMT Base for professional clinical settings, the in-development D-Pocket handheld consumer device, the in-development D-Sensor miniaturized wearable sensor (co-developed with Samsung), and the Diamoki companion health-tracking app.

Product overview

DiaMonTech AG offers a portfolio of non-invasive blood glucose monitoring products built on its proprietary mid-infrared quantum cascade laser (QCL) technology and patented IRE-PTD (Infrared Excited — Photothermal Detection) method. The core product line consists of three distinct devices: the DMT Base, a CE-certified stationary device for professional clinical environments (diabetes centers); the D-Pocket, a handheld consumer device approximately the size of a smartphone — the flagship portable product currently in development; and the D-Sensor, a miniaturized wearable sensor being developed in partnership with Samsung for integration into smartwatches. These devices share a common underlying technology platform — mid-infrared spectroscopy scanning interstitial fluid in the skin to detect glucose molecules via a heat-wave detection process — but serve different form factors and market segments. Complementing the hardware products, the companion mobile app Diamoki enables users to track glucose, blood pressure, diet, activity, weight/BMI, and medication, with automatic import from health apps and glucometers, providing a unified data analytics layer across the product ecosystem. The company also holds ISO 13485:2016 and ISO 27001:2017 certifications, and has filed over 100 patents globally.

Differentiator

Problem solved

Functional benefit

Brands

  • D-Pocket: Handheld non-invasive blood glucose monitoring device, smartphone-sized, currently in development. Uses mid-infrared laser technology and photothermal detection for pain-free glucose measurement.
  • D-Sensor
  • Diamoki
  • DMT Base

Products and services

  • DMT Base (D-Base) Non-invasive, CE-certified medical device for professional blood glucose monitoring using mid-infrared QCL laser spectroscopy and patented IRE-PTD photothermal detection. Designed for diabetes centers and clinical settings, providing needle-free, consumable-free glucose measurement with 99.1% clinical accuracy.
  • D-Pocket Handheld, smartphone-sized, non-invasive blood glucose monitor for consumer use. Uses patented mid-infrared QCL + IRE-PTD technology to deliver pain-free glucose readings within 10–15 seconds without test strips or other consumables. Achieves clinical-grade accuracy comparable to early invasive CGM devices (MARD 20.7% and 19.6%).
  • D-Sensor Miniaturized non-invasive glucose sensor under development with Samsung for integration into smartwatches and wearable devices. Extends DiaMonTech's mid-infrared laser and photothermal detection technology into a continuous-monitoring form factor for both diabetes patients and health-conscious users.
  • Diamoki Companion mobile app for diabetes management that tracks blood glucose, blood pressure, diet, activity, weight/BMI, and medication, with automatic import from health apps and glucose meters. Provides trend visualization and structured health-data analytics as the software layer across DiaMonTech's device ecosystem.

Quantifiable outcome

  • MARD (Mean Absolute Relative Difference) values of 20.7% and 19.6% - comparable to early invasive CGM devices approved by FDA and Notified Body in EU
  • +4 more outcomes

Companies that use DiaMonTech AG

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

DiaMonTech AG technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

DiaMonTech AG partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • German Accelerator Life Sciences ProgramcoreStrategic or Co-development Partner · 1 January 2024Market access initiative for life sciences startups to assist in US market navigation, providing expert mentorship and strategic connections. Supports DiaMonTech's international expansion goals.
  • HanseMerkurcoreStrategic or Co-development Partner · 29 September 2020One of Germany's largest private health insurance companies (€2.3 billion annual revenue) plans strategic cooperation to provide non-invasive blood glucose measurement to insured customers. First pilot projects for insulin-dependent diabetics planned for 2021. HanseMerkur sees potential for early diabetes detection using DiaMonTech technology.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

DiaMonTech AG competitors and assessment

Company assessment

Broad incumbents

  • Dexcom: Leading CGM manufacturer (G6, G7) with the strongest accuracy credentials (MARD ~8%) and deepest payer/reimbursement relationships. Broad incumbent and the gold-standard comparison point for any non-invasive entrant; could pursue non-invasive R&D leveraging its clinical evidence base.
  • Roche Diabetes Care: Manufacturer of Accu-Chek blood glucose meters and one of the largest traditional BGM incumbents globally. Broad incumbent in glucose monitoring with established pharmacy distribution; potential competitor if the company pursues non-invasive BGM replacement or partners with non-invasive entrants.
  • Abbott Diabetes Care: Manufacturer of FreeStyle Libre, the dominant CGM with 5M+ global users and established retail/payer distribution. Broad incumbent in glucose monitoring that DiaMonTech positions itself against in accuracy comparisons; any Abbott move into non-invasive would directly threaten DiaMonTech's window.
  • Medtronic Diabetes: Major medical device incumbent offering Guardian Connect CGM and insulin pumps. Broad incumbent in diabetes care with substantial R&D resources and integrated insulin-delivery ecosystem; any pivot to non-invasive CGM would directly compete with DiaMonTech's professional and consumer offerings.

Emerging players

  • Afon Technology: Welsh startup developing a non-invasive wearable continuous glucose monitor using proprietary electromagnetic sensing. Early-stage peer pursuing similar miniaturized, no-consumable, continuous monitoring vision as DiaMonTech's D-Sensor program, providing comparable technology-risk profile.
  • Senseonics: Developer of Eversense, the only implantable long-term CGM (180-day sensor). Emerging player pursuing alternative continuous monitoring approaches with comparable accuracy to traditional CGMs but via invasive subcutaneous implantation — represents adjacent technology risk if DiaMonTech's non-invasive accuracy falls short.
  • LifePlus: Developer of LifeLeaf, a non-invasive continuous glucose monitoring wearable. Emerging player pursuing similar smartwatch/wearable form factor as DiaMonTech's D-Sensor, though at earlier commercialization stage with different underlying technology.

Direct peers

  • Know Labs: US-based company developing non-invasive glucose monitoring using radiofrequency spectroscopy and its Bio-RFID sensor technology. Closest direct peer to DiaMonTech given its focus on truly non-invasive continuous glucose monitoring for consumer use, pursuing similar FDA pathways and consumer launch timeline.
  • Nemaura Medical: UK-based developer of sugarBEAT, a non-invasive continuous glucose monitor using a disposable skin patch. Direct competitor in the non-invasive glucose monitoring space targeting both consumer wellness and medical-grade applications, providing useful comparability on regulatory timelines and consumer adoption rates.
  • Integrity Applications (GlucoTrack): Israeli company that developed GlucoTrack, a non-invasive glucose monitor combining ultrasonic, electromagnetic, and thermal sensors for ear-clip measurement. Direct peer despite using different sensing modalities — represents the long history of attempted non-invasive glucose commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

DiaMonTech AG social profiles

Digital presence

DiaMonTech AG compliance and trust

Trust signal

Compliance3 records

DiaMonTech AG financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DiaMonTech AG leadership team

Management profile

Number of profiles

Profiles11 records

DiaMonTech AG funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DiaMonTech AG M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DiaMonTech AG

What does DiaMonTech AG do?

DiaMonTech AG develops and is commercializing medical devices for non-invasive blood glucose measurement using proprietary mid-infrared quantum cascade laser spectroscopy and its patented IRE-PTD photothermal detection method. Its current portfolio includes the CE-certified DMT Base for professional clinical settings, the in-development D-Pocket handheld consumer device, the in-development D-Sensor miniaturized wearable sensor (co-developed with Samsung), and the Diamoki companion health-tracking app.

Is DiaMonTech AG a public or private company?

DiaMonTech AG is a private company. It is classified as venture growth investor backed and is currently operating.

When was DiaMonTech AG founded?

DiaMonTech AG was founded in 2015. It employs 11 to 50 people.

Where is DiaMonTech AG based?

DiaMonTech AG is headquartered in Berlin, Germany, in the Europe region.

How does DiaMonTech AG make money?

Five revenue lines are on record. Hardware Sales - D-Pocket is the primary driver. The others are hardware Sales - D-Base/DMT Base, D-Sensor Wearable Technology, diamoki App - Companion Software and strategic Healthcare Partnerships.

Who are DiaMonTech AG's main competitors?

Broad incumbents on record are Dexcom, Roche Diabetes Care, Abbott Diabetes Care and Medtronic Diabetes. Emerging players are Afon Technology, Senseonics and LifePlus. Direct peers are Know Labs, Nemaura Medical and Integrity Applications (GlucoTrack).

Does DiaMonTech AG have an API?

No public API is recorded for DiaMonTech AG.

What industry is DiaMonTech AG in?

DiaMonTech AG's product category is Medical Devices / Non-Invasive Blood Glucose Monitoring. Its primary akta.pro industry code is HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips, with a secondary code of HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AZoOpticsPhotonics Start-Ups Powering Europe’s InnovationEurope’s photonics start-up scene has gained momentum, with 240 new companies identified since 2024 and a total of 556 active firms, according to data from Photonics21. Start-ups like DiaMonTech are developing innovative technologies, such as non-invasive diabetes monitoring, addressing significant societal challenges. The report highlights the importance of securing funding to support the growth of these firms in the competitive fields of AI, health, and green energy.MassDeviceDiaMonTech raises $5M for laser-based blood glucose detection systemDiaMonTech raised $5 million to further develop its laser-based blood glucose detection system, increasing its total funding to over $20 million. The company, based in Berlin, Germany, utilizes patented mid-infrared technology for non-invasive blood glucose measurement. The technology is designed for ease of use, comparable to smartphone fingerprint sensors.AxiosDiabetes monitoring without the needleDiaMonTech is developing a bloodless glucose monitoring system using lasers and an optical lens to read glucose levels through the skin. The company has a lab-based version certified for medical use in Europe and is working on a hand-held device, potentially ready by 2022. Researchers are also pursuing an artificial pancreas, though that remains years away.openPR.comNon-Invasive Blood Glucose Monitoring Devices Market Expansion to be Persistent During 2026 By Top Companies DiaMonTech GmbH, Nemaura Medical, Integrity Applications, CNOGA Medical Ltd., Breath HealthThe global non-invasive blood glucose monitoring devices market was valued at $5.1 million in 2017 and is projected to grow at a 35% CAGR through 2026. Growth is driven by rising diabetes prevalence and regulatory support, though device accuracy remains a barrier. North America is expected to be the most lucrative region.